Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)
- Citation:
- Leuk Lymphoma vol 56 (4) 958-964
- Year:
- 2015
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- 813 is parent abstract
- Pharmas:
- Grants:
- U10 CA032291, CA33601, U10 CA077658, U10 CA045808, U10 CA031946, U10 CA033601, U10 CA180821, U10 CA077597, U10 CA045418, U10 CA077440, U10 CA041287, U10 CA180833, U10 CA047642, CA31946, U10 CA003927
- Corr. Author:
- Authors:
- Vicki A. Morrison Sin-Ho Jung Jeffrey Johnson Ann LaCasce Kristie A. Blum Nancy L. Bartlett Brandelyn N. Pitcher Bruce D. Cheson
- Networks:
- Study
- CALGB-50501
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- mantle cell lymphoma, bortezomib, lenalidomide